

# Anti-CD20 (Ofatumumab), Human IgG1 Antibody

07/20

---

**CATALOG NO.:** A2172-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a human IgG1 kappa monoclonal antibody that acts as a CD20 antagonist. CD20 is usually expressed on pre- and mature B lymphocytes, as well as malignant B lymphocytes. The Fab domain of the antibody binds to the large and small extracellular loops of the CD20 molecule but does not cause immediate shedding and internalization of CD20. Instead, the binding persists on B cell surface for an extended time, which helps recruit innate effectors such as macrophages that induce complement-dependent and antibody-dependent cellular cytotoxicity and cause B cell lysis. The original drug was approved by the FDA to treat progressive or recurrent chronic lymphocytic leukemia (CLL) or CLL patients who were refractory to fludarabine-based therapy.

**ALTERNATE NAMES:** HuMax-CD20, 2F2, B1, S7, Bp35, CVID5, MS4A2, LEU-16, MS4A1

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG1, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human CD20

**CAS NUMBER:** 679818-59-8

**MOLECULAR WEIGHT:** 146.1 kDa

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-CD20 (Rituximab), Chimeric Antibody (A1049)  
 Anti-CTLA-4 (Ipilimumab), Humanized Antibody (A2110)  
 Anti-CD4 (Campath-9H), Rabbit IgG, kappa Antibody (A2012)  
 Anti-EGFR (Panitumumab), Humanized Antibody (A1050)  
 Anti-EGFR (Cetuximab), Chimeric Antibody (A1047)

**FOR RESEARCH USE ONLY! Not to be used on humans.**